![Quiver Logo](/static/img/logo-icon.png)
![GTBP logo](https://quiver-logos.s3.us-east-2.amazonaws.com/gtbp.png)
GT Biopharma Inc. Common Stock
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. It is engaged in discovering, developing, and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view GTBP Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.
Recent trades of GTBP by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by GTBP's directors and management
Government lobbying spending instances
New patents grants
Federal grants, loans, and purchases
Recent insights relating to GTBP
Recent picks made for GTBP stock on CNBC
ETFs with the largest estimated holdings in GTBP
Flights by private jets registered to GTBP
![Quiver Logo](/static/img/logo-icon.png)